source
- Revolution Medicines begins shipping experimental pancreatic cancer drug daraxonrasib under FDA early access programRevolution Medicines announced that it has started sending its experimental pancreatic cancer therapy, daraxonrasib, to doctors and patients through an FDA‑authorized early access program. The comp…
- BioNTech and Pfizer present bispecific cancer data at ASCO, FDA chief notes optimismAt the American Society of Clinical Oncology meeting, BioNTech and Pfizer highlighted early results from bispecific antibody programs aimed at lung cancer. The companies described the data as promi…